John McKearn has been promoted to CEO of Kalypsys, the San Diego-based company said last week.

McKearn joined the company in 2003 as chief scientific officer and became Kalypsys’ president in 2004. Prior to his employment with Kalypsys, he was senior vice president of research at Pharmacia. He has also held senior positions at G.D. Searle, the pharmaceutical subsidiary of Monsanto, Kalypsys said. McKearn holds a PhD in immunology from the University of Chicago and a bachelor’s degree from Northern Illinois University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.